The therapeutic potential of the proteasome in leukaemia
- 6 March 2008
- journal article
- review article
- Published by Wiley in Hematological Oncology
- Vol. 26 (2), 73-81
- https://doi.org/10.1002/hon.848
Abstract
Many cellular processes converge on the proteasome, and its key regulatory role is increasingly being recognized. Proteasome inhibition allows the manipulation of many cellular pathways including apoptotic and cell cycle mechanisms. The proteasome inhibitor bortezomib has enhanced responses in newly diagnosed patients with myeloma and provides a new line of therapy in relapsed and refractory patients. Malignant cells are more sensitive to proteasome inhibition than normal haematopoietic cells. Proteasome inhibition enhances many conventional therapies and its role in leukaemia is promising. Copyright © 2008 John Wiley & Sons, Ltd.Keywords
This publication has 99 references indexed in Scilit:
- NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cellsBlood, 2007
- The proteasome inhibitors bortezomib and PR‐171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cellsBritish Journal of Haematology, 2007
- Global Organization and Function of Mammalian Cytosolic Proteasome Pools: Implications for PA28 and 19S Regulatory ComplexesMolecular Biology of the Cell, 2006
- A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemiaBlood, 2006
- Comprehensive quantitative proteome analysis of 20S proteasome subtypes from rat liver by isotope coded affinity tag and 2-D gel-based approachesProteomics, 2006
- Distinct functions of the ubiquitin–proteasome pathway influence nucleotide excision repairThe EMBO Journal, 2006
- Proteasome Activator PA200 Is Required for Normal SpermatogenesisMolecular and Cellular Biology, 2006
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- PAD combination therapy (PS‐341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myelomaBritish Journal of Haematology, 2005
- Proline- and Arginine-Rich Peptides Constitute a Novel Class of Allosteric Inhibitors of Proteasome ActivityBiochemistry, 2003